Практические Рекомендации По Лекарственному Лечению Рака Ободочной Кишки И Ректосигмоидного Соединения

Федянин, М. Ю.; Ачкасов, С. И.; Болотина, Л. В.; Гладков, О. А.; Глебовская, В. В.; Гордеев, С. С.; Карачун, А. М.; Козлов, Н. А.; Любченко, Л. Н.; Малихова, О. А.; Мамедли, З. З.; Медведева, Б. М.; Obukhova, Olga A.; Петров, А. С.; Подлужный, Д. В.; Проценко, С. А.; Рыжков, А. Д.; Рыков, И. В.; Сидоров, Д. В.; Трякин, А. А.; Цуканов, А. С.; Шелыгин, Ю. А.

doi:10.18027/2224-5057-2021-11-3s2-22

Cited by 8 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Затем, не позднее 4-х недель после операции, паци-ентам назначается программа адъювантной химиотерапии с целью исключения микрометастазирования и снижения риска местного рецидива. Лекарственная терапия проводится циклично, каждые 14 дней, при отсутствии противопоказаний к лечению на протяжении шести месяцев [4][5][6].…”

Section: Introductionunclassified

“…Неотъемлемым компонентом любой схемы цитотоксической лекарственной терапии, назначаемой при раке ободочной кишки и ректосигмоидного отдела, является 5-фторурацил [1,[3][4][5][6][7]. Препарат представляет собой антиметаболит пиримидинового основания -урацила, входящего в состав нуклеотидов на азотистых основаниях.…”

Section: Introductionunclassified

See 1 more Smart Citation

Erosive-ulcerative lesions of the mucous membrane of the stomach and duodenum during therapy with 5-fluorouracil

Yakimenko

Kutukov

Antonyan

et al. 2022

jour

View full text Add to dashboard Cite

Introduction. Adjuvant therapy with the inclusion of 5-fluorouracil is used in patients with neoplasms of the colon and rectosigmoid in the postoperative period. However, along with a positive antitumor effect, 5-fluorouracilcontaining regimens have a negative effect on the mucosa of the gastrointestinal tract, which often leads to the need to replace or cancel drugs, thereby reducing the effectiveness of treatment.Aim of the study was to improve the idea of the possibility of erosive and ulcerative lesions of the stomach and duodenum during treatment with 5-fluorouracil in patients with malignant tumors of the colon and rectosigmoid and the factors that aggravate their course, as well as to highlight the problem of prevention and treatment of gastrointestinal complications.Materials and methods The search for publications by keywords was carried out in the databases of PubMed, Google Scholar, elibrary.ru and Russian specialized journals related to therapy, surgery, gastroenterology, oncology for the period from 2010 to 2022.Results and Discussion An analysis of the literature allows us to conclude that the risk of damage to the mucous membrane of the stomach and duodenum during the use of chemotherapy with the inclusion of 5-fluorouracil is very high and amounts to 30–40 %. In addition, there are many factors that can complicate the course of this undesirable phenomenon. These include the advanced age of patients, the presence of serious comorbidity and postoperative complications in patients, as well as infection with Helicobacter pylori. The lack of generally accepted recommendations for the prevention and treatment of damage to the lining of the stomach and duodenum during the use of chemotherapy is a serious problem in modern medical practice.Conclusion Gastrointestinal toxicity associated with the use of 5-fluorouracil in the form of mucositis in patients with malignant neoplasms of the colon and rectosigmoid deserves close attention. The presence of damage to the mucous membrane of the stomach and duodenum in a patient requires immediate therapy, as this will improve the long-term results of the treatment of the underlying disease and ensure a high quality of life for the patient.

show abstract

Section: Introductionunclassified

Erosive-ulcerative lesions of the mucous membrane of the stomach and duodenum during therapy with 5-fluorouracil

Yakimenko

Kutukov

Antonyan

et al. 2022

jour

View full text Add to dashboard Cite

show abstract

“…В структуре онкологических заболеваний новообразования ободочной кишки и ректосигмоидного отдела занимают ведущие позиции по заболеваемости [1,2,3]. Согласно статистическим данным на протяжении последнего десятилетия этот показатель неуклонно растет [1,2,3] [4,5,6]. Неотъемлемым компонентом любой схемы цитотоксической лекарственной терапии, назначаемой при раке ободочной кишки и ректосигмоидного отдела, является 5-фторурацил [1,3,4,5,6,7].…”

unclassified

Профилактика Гастроинтестинальных Нежелательных Явлений Во Время Терапии 5-Фторурацилом

Кутуков¹,

Антонян²,

Якименко³

et al. 2022

Профилактика Гастроинтестинальных Нежелательных Явлений Во Время Терапии 5-Фторурацилом

View full text Add to dashboard Cite

Gastrointestinal toxicity arising from the use of 5-fluorouracil in the form of mucositis in patients with malignant neoplasms of the colon and rectosigmoid deserves close attention. An analysis of the literature allows us to conclude that the risk of damage to the mucous membrane of the stomach and duodenum during the use of chemotherapy with the inclusion of 5-fluorouracil is very high and amounts to 30-40%. In addition, there are many factors that can complicate the course of this undesirable phenomenon. These include the advanced age of patients, the presence of serious comorbidity and postoperative complications in patients, as well as infection with Helicobacter pylori. The lack of generally accepted recommendations for the prevention and treatment of damage to the lining of the stomach and duodenum during the use of chemotherapy is a serious problem in modern medical practice.

show abstract

“…В случае развития резистентности к первым 2 линиям терапии современные рекомендации предлагают использовать несколько стратегий выбора дальнейшего лечения, включающих повторное назначение препаратов или схем, поиск редких и экспериментальных мишеней (NTRK, MSI, MGMT, PIK3CA, ALK и т.д.) и применение зарегистрированных препаратов 3-й линии -регорафениба и TAS-102 (не зарегистрирован в России) [4,5].…”

unclassified

“…Постепенная эскалация доз позволила достичь меньшей токсичности при сохранении эффективности. В настоящее время подход с постепенной эскалацией дозы регорафениба наиболее часто применяется в клинической практике [4].…”

unclassified

The third-line therapy for patients with metastatic colorectal cancer: regorafenib or repeated administration of drugs? A review

Рыков

Чубенко²

2022

J. Mod. Onco.

View full text Add to dashboard Cite

To this date, the treatment of metastatic colorectal cancer involves continuous drug therapy, the so-called "continuum of care" approach in order to control of tumor growth and try to increase life expectancy for patients. The characteristic is the limited availability and insufficient number of third- and subsequent-line therapy. The main options for the treatment of resistant forms of metastatic colorectal cancer in real practice are the alternation of chemotherapy regimens, targeted drugs and the application of regorafenib. The choice of the treatment tactics is influenced by the patient's condition, the previous treatment and the efficacy, the molecular status of the tumor. The correct sequence of use of such approaches is currently not clearly defined and is the subject of many discussions and retrospective studies. The article discusses the main trends in the application of targeted antiangiogenic therapy for this category of patients.

show abstract

Практические Рекомендации По Лекарственному Лечению Рака Ободочной Кишки И Ректосигмоидного Соединения

Abstract: .

Cited by 8 publications

References 0 publications

Erosive-ulcerative lesions of the mucous membrane of the stomach and duodenum during therapy with 5-fluorouracil

Erosive-ulcerative lesions of the mucous membrane of the stomach and duodenum during therapy with 5-fluorouracil

Профилактика Гастроинтестинальных Нежелательных Явлений Во Время Терапии 5-Фторурацилом

The third-line therapy for patients with metastatic colorectal cancer: regorafenib or repeated administration of drugs? A review

Contact Info

Product

Resources

About